Pleural Mesothelioma
Oncology·MeSH: Fallopian Tube Neoplasms
Prevalence
1.0 / 100K
Incidence
0.9 / 100K/yr
3 drugs in development·3 companies·4 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Alimta® | ELI LILLY & Co (LLY) |
Phase 3(1)
| Drug | Company |
|---|---|
| Fianlimab | Merus N.V. (MRUS) |
Phase 2(1)
| Drug | Company |
|---|---|
| thor-707 | Sanofi (SNY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Pleural Mesothelioma?
BioSniper tracks 3 drugs in development for Pleural Mesothelioma across 3 companies.
How many clinical trials target Pleural Mesothelioma?
There are 4 clinical trials targeting Pleural Mesothelioma tracked by BioSniper.
What is the prevalence of Pleural Mesothelioma?
The estimated prevalence of Pleural Mesothelioma is approximately 1.0 per 100,000 population.
Deep-dive into Pleural Mesothelioma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis